Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study no. 30865.
Patients with hormone escaped advanced progressive prostate cancer were randomized either to receive either high-dose Estramustine phosphate orally or Mitomycin C by i.v. injection every 6 weeks until signs of progression or death supervened. Patients on both arms progressed rapidly, with a median time to progression of 5 months and a median length of survival of only 10 months. Toxicity was very considerable in both arms.
Newling
D W
DW
Princess Royal Hospital, Hull, England.
Fossa
S
S
Tunn
U
U
Kurth
K H
KH
De Pauw
M
M
Sylvester
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000556:secondary; D012307:Risk Factors; D016019:Survival Analysis
D008937:Mitomycins; D004961:Estramustine; D016685:Mitomycin